Physician profile
Shaina Rozell
NPI 1508187253
$366,307.02
in general payments reported to CMS, 2019-2025
79 companies · $96K in 2025
The $96K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,429 · 2020: $978 · 2021: $1,680 · 2022: $18K · 2023: $99K · 2024: $148K · 2025: $96K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $265K · Travel and Lodging: $38K · Consulting Fee: $21K · Food and Beverage: $16K · Honoraria: $1,750 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $264,625.00 |
| Travel and Lodging | $38,256.02 |
| Consulting Fee | $21,326.50 |
| Food and Beverage | $15,808.81 |
| Honoraria | $1,750.00 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $339.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $206,225.28 | 2019-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals Lp | $92,373.55 | 2019-2025 | Enhertu, Lynparza, Datroway |
| Daiichi Sankyo INC. | $42,429.23 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $4,602.09 | 2019-2025 | Kisqali |
| Regeneron Healthcare Solutions, INC. | $3,956.47 | 2020-2025 | Libtayo |
| Pfizer INC. | $2,775.75 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,972.50 | 2021-2024 | Ojjaara, Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $1,300.32 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Janssen Biotech, INC. | $936.91 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $846.01 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $805.88 | 2019-2025 | Opdivo, Eliquis, Opdualag |
| Seagen INC. | $600.90 | 2019-2025 | Padcev, Tukysa |
| Amgen INC. | $598.18 | 2019-2025 | Kyprolis, Lumakras, Blincyto |
| Lilly USA, LLC | $555.57 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $485.47 | 2019-2025 | Venclexta, Tecentriq, Alecensa |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $322.35 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $275.78 | 2019-2023 | Imbruvica, Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $267.79 | 2023-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Astellas Pharma US INC | $234.69 | 2021-2025 | Padcev, Xtandi |
| Exelixis INC. | $232.90 | 2019-2025 | Cabometyx |
| Genzyme Corporation | $225.89 | 2021-2025 | |
| Celgene Corporation | $220.15 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Eisai INC. | $216.19 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $186.37 | 2019-2024 | Ultomiris |
| Tersera Therapeutics LLC | $160.12 | 2022-2025 | Xermelo, Zoladex |
| Ipsen Biopharmaceuticals, INC | $142.63 | 2019-2025 | Onivyde, Tazverik |
| Jazz Pharmaceuticals INC. | $141.43 | 2020-2024 | |
| Deciphera Pharmaceuticals INC. | $132.20 | 2023-2025 | Qinlock, Romvimza |
| Global Blood Therapeutics, INC. | $131.15 | 2020-2022 | |
| Emd Serono, INC. | $131.00 | 2019-2024 | Bavencio, Tepmetko |
| Rigel Pharmaceuticals, INC. | $130.50 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Puma Biotechnology, INC. | $121.28 | 2019-2025 | |
| Tempus Ai, INC | $116.43 | 2024 | |
| Beigene USA, INC. | $104.95 | 2022-2025 | Brukinsa, Tevimbra |
| Myriad Genetic Laboratories, INC. | $104.66 | 2022 | |
| Pharmacosmos Therapeutics INC. | $103.99 | 2022-2024 | Cosela |
| Karyopharm Therapeutics INC. | $101.39 | 2023-2025 | Xpovio |
| Sanofi-Aventis U.S. LLC | $99.00 | 2021 | |
| Stemline Therapeutics INC. | $96.66 | 2025 | Orserdu |
| G1 Therapeutics, INC. | $90.12 | 2022-2023 | Cosela |
| Novo Nordisk INC | $83.36 | 2019-2023 | |
| Beone Medicines USA, INC. | $81.62 | 2025 | Brukinsa |
| Amneal Pharmaceuticals LLC | $80.73 | 2024-2025 | Alymsys, Avastin |
| Kite Pharma, INC. | $72.00 | 2022-2024 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $71.91 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $71.83 | 2023-2025 | Orgovyx |
| Sobi, INC | $66.71 | 2022-2024 | |
| Morphosys, US INC. | $64.65 | 2022-2023 | Monjuvi |
| Amag Pharmaceuticals, INC. | $62.36 | 2019-2021 | |
| Agios Pharmaceuticals, INC. | $61.11 | 2024-2025 | Pyrukynd |
| Array Biopharma INC | $59.72 | 2025 | Lorbrena, Mektovi, Braftovi |
| Ge Healthcare | $59.72 | 2021-2024 | |
| Mirati Therapeutics, INC. | $55.42 | 2023-2024 | Krazati |
| Blueprint Medicines Corporation | $55.19 | 2023-2025 | Ayvakit |
| Janssen Pharmaceuticals, INC | $53.99 | 2019-2021 | |
| Immunogen, INC. | $53.12 | 2023-2024 | Elahere, Elahere |
| Coherus Oncology, INC. | $51.10 | 2022-2025 | Loqtorzi |
| Taiho Oncology, INC. | $48.89 | 2019-2025 | |
| Dova Pharmaceuticals | $47.27 | 2020-2021 | |
| Servier Pharmaceuticals LLC | $40.00 | 2024 | |
| Aveo Pharmaceuticals, INC. | $39.64 | 2022-2025 | |
| Pharmaand Gmbh | $36.84 | 2025 | Rubraca |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.79 | 2019-2025 | |
| Adc Therapeutics America, INC. | $34.17 | 2025 | |
| Geron Corporation | $33.60 | 2025 | Rytelo |
| Tactile Systems Technology INC | $33.17 | 2019 | |
| Pharmaessentia USA Corporation | $31.05 | 2025 | Besremi |
| Clovis Oncology, INC. | $30.95 | 2019 | |
| Springworks Therapeutics, INC. | $28.03 | 2024 | Ogsiveo |
| Immunocore Limited | $28.01 | 2025 | Kimmtrak |
| Cti Biopharma Corp. | $25.23 | 2022 | |
| Tesaro, INC. | $24.74 | 2019 | |
| Genmab U.S., INC. | $23.64 | 2023 | Epkinly |
| Legend Biotech USA INC. | $23.22 | 2025 | Carvykti |
| Advanced Accelerator Applications | $22.24 | 2020 | |
| Recordati_rare_diseases_inc. | $17.83 | 2025 | Enjaymo |
| Tolmar, INC. | $15.89 | 2025 | Rubraca |
| Myovant Sciences INC. | $15.38 | 2021 | |
| Medtronic USA, INC. | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaina Rozell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.